Get started
Author

Hayato Kawamura

ORCID: 0000-0002-7679-4279
Observed ORCID: 0000-0002-7679-4279
OpenAlex ID: A5068438828
The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
2023 · Sho Matoya, Takanori Suzuki, et al. · Hepatology Research · 24
PDF
Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis
2024 · Takanori Suzuki, Kentaro Matsuura, et al. · Journal of Gastroenterology and Hepatology · 11
PDF
Neutrophil‐to‐lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis
2025 · Takanori Suzuki, Kentaro Matsuura, et al. · Hepatology Research · 10
Efficacy of Mucosal Cutting Biopsy for the Histopathological Diagnosis of Gastric Submucosal Tumors
2019 · Akihisa Adachi, Yoshikazu Hirata, et al. · Case Reports in Gastroenterology · 9
PDF
Prognostic Nutritional Index after Introduction of Atezolizumab with Bevacizumab Predicts Prognosis in Advanced Hepatocellular Carcinoma: A Multicenter Study
2024 · Takanori Suzuki, Kentaro Matsuura, et al. · Oncology · 8
Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis
2023 · Takanori Suzuki, Kentaro Matsuura, et al. · Cancer Medicine · 7
PDF
Kinetics of HBcrAg and HBsAg using highly sensitive iTACT assays in chronic hepatitis B patients with HBsAg seroclearance
2023 · Takanori Suzuki, Kentaro Matsuura, et al. · Journal of Medical Virology · 7
Serum inducible protein 10 kDa/C‐X‐C motif chemokine 10 levels predict regression of M2BPGi‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents
2023 · Yoshihito Nagura, Takanori Suzuki, et al. · Hepatology Research · 7
PDF
The Neutrophil-to-Lymphocyte Ratio during Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Long-Term Therapeutic Efficacy: A Multicenter Analysis
2025 · Ryo Sato, Takanori Suzuki, et al. · Oncology · 6
Hepatic stellate cell inhibition by angiotensin II receptor blocker mitigates liver injury and fibrosis via NF-κB-galectin-3 suppression in a rat nonalcoholic steatohepatitis model
2025 · Xiaochen Kuang, Aya Naiki-Ito, et al. · Archives of Toxicology · 5
PDF
Clinical performance of Circulating HBV RNA and iTACT‐HBcrAg Assays in HBeAg‐negative and HBsAg‐cleared Chronic Hepatitis B Patients
2024 · Takanori Suzuki, Kentaro Matsuura, et al. · Journal of Medical Virology · 4
Number of Tumors Stratifies the Therapeutic Response to Atezolizumab plus Bevacizumab Therapy in Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
2025 · Takanori Suzuki, Kentaro Matsuura, et al. · Oncology · 3
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs
2024 · Takanori Suzuki, Kentaro Matsuura, et al. · Hepatology Research · 3
Efficacy of antiviral therapy for the prevention of mother‐to‐child transmission of hepatitis B virus and the risk of postpartum hepatitis flare after discontinuation of antiviral therapy
2024 · Hayato Kawamura, Kentaro Matsuura, et al. · Hepatology Research · 3
PDF
Serum Angiopoietin-2 Levels Predict the Development of Hepatocellular Carcinoma following Hepatitis C Virus Eradication Using Direct-Acting Antiviral Agents
2024 · Takanori Suzuki, Kentaro Matsuura, et al. · Oncology · 3
Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation
2022 · Takanori Suzuki, Kentaro Matsuura, et al. · Hepatology Research · 3
PDF
The Low Platelet Count at the Start of Atezolizumab Plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma Predicts Deteriorated Liver Function at the Time of Disease Progression Thereafter: A Multicenter Analysis
2025 · Ryo Sato, Takanori Suzuki, et al. · Hepatology Research · 2
The Effectiveness of Long-Term Continuation of Atezolizumab plus Bevacizumab in Patients Receiving Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: A Multicenter Study
2025 · Takanori Suzuki, Kiyoto Narita, et al. · Oncology · 2
PDF
MicroRNA-223-3p levels in serum-derived extracellular vesicles predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agents
2024 · Takanori Suzuki, Kentaro Matsuura, et al. · Journal of Gastroenterology · 2
Adult-onset Type II Citrullinemia Developed under Dietary Restrictions during Imprisonment
2023 · Takanori Suzuki, Kentaro Matsuura, et al. · Internal Medicine · 2
PDF
Eosinophilic pancreatitis presenting as rupture of a pancreatic cystic lesion into the chest cavity
2021 · Hayato Kawamura, Hiroki Takada, et al. · Clinical Journal of Gastroenterology · 2
Contrast‐Enhanced Computed Tomography/Magnetic Resonance Imaging Is Useful for Surveying Gastroesophageal Varices in Patients After Fontan Surgery
2025 · Takanori Suzuki, Kentaro Matsuura, et al. · Hepatology Research · 1
PDF
Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study
2024 · Daisuke Kato, Takanori Suzuki, et al. · Oncology · 1
De novo hepatitis B in a patient with negative hepatitis B core antibody and high normal range hepatitis B surface antibody treated with R-CHOP therapy for Diffuse large B-cell lymphoma
2024 · Hayato Kawamura, Satoshi Sobue, et al. · Kanzo · 1
PDF
Adult-onset Still's Disease (AOSD) with Gastrointestinal Lesions
2024 · Takahito Harada, Yoshikazu Hirata, et al. · Internal Medicine · 1
PDF
Works count: 37
Citation count: 127
H-index: 7
I10-index: 3
Year
Topic
Type